Greg Elmer

Greg Elmer

Auto-generated profile, based on publicly available information

Greg Elmer

Department of Psychiatry, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2001 in Behavioural Brain Research
Verified
Journal Article
Closed access
YBYoav Benjamini
Yoav Benjamini
DDDan Drai
Dan Drai
GEGreg Elmer
Greg Elmer
NKNeri Kafkafi
Neri Kafkafi
IGIlan Golani
Ilan Golani

4 May 2016 in Nature
Verified
Journal Article
Open access
PDF file
PZPanos Zanos
Panos Zanos
RMRuin Moaddel
Ruin Moaddel
PMPatrick J. Morris
Patrick J. Morris
PGPolymnia Georgiou
Polymnia Georgiou
JFJonathan Fischell
Jonathan Fischell
TGTodd D. Gould
Todd D. Gould
Major depressive disorder affects around 16 per cent of the world population at some point in their lives. Despite the availability of numerous monoaminergic-based antidepressants, most patients require several weeks, if not months, to respond to these treatments, and many patients never attain sustained remission of their symptoms. The non-competitive, glutamatergic NMDAR (N-methyl-d-aspartate receptor) antagonist (R,S)-ketamine exerts rapid and sustained antidepressant effects after a single dose in patients with depression, but its use is associated with undesirable side effects. Here we show that the metabolism of (R,S)-ketamine to (2S,6S;2R,6R)-hydroxynorketamine (HNK) is essential for its antidepressant effects, and that the (2R,6R)-HNK enantiomer exerts behavioural, electroencephalographic, electrophysiological and cellular antidepressant-related actions in mice. These antidepressant actions are independent of NMDAR inhibition but involve early and sustained activation of AMPARs (α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors). We also establish that (2R,6R)-HNK lacks ketamine-related side effects. Our data implicate a novel mechanism underlying the antidepressant properties of (R,S)-ketamine and have relevance for the development of next-generation, rapid-acting antidepressants.

1 March 1999 in Pain
Verified
Journal Article
Closed access
JMJeffrey S Mogil
Jeffrey S Mogil
SWSonya G Wilson
Sonya G Wilson
KBKarine Bon
Karine Bon
SLSeo Eun Lee
Seo Eun Lee
KCKyungsoon Chung
Kyungsoon Chung
MDMarshall Devor
Marshall Devor
It is generally acknowledged that humans display highly variable sensitivity to pain, including variable responses to identical injuries or pathologies. The possible contribution of genetic factors has, however, been largely overlooked. An emerging rodent literature documents the importance of genotype in mediating basal nociceptive sensitivity, in establishing a predisposition to neuropathic pain following neural injury, and in determining sensitivity to pharmacological agents and endogenous antinociception. One clear finding from these studies is that the effect of genotype is at least partially specific to the nociceptive assay being considered. In this report we begin to systematically describe and characterize genetic variability of nociception in a mammalian species, Mus musculus. We tested 11 readily-available inbred mouse strains (129/J, A/J, AKR/J, BALB/cJ, C3H/HeJ, C57BL/6J, C58/J, CBA/J, DBA/2J, RIIIS/J and SM/J) using 12 common measures of nociception. These included assays for thermal nociception (hot plate, Hargreaves' test, tail withdrawal), mechanical nociception (von Frey filaments), chemical nociception (abdominal constriction, carrageenan, formalin), and neuropathic pain (autotomy, Chung model peripheral nerve injury). We demonstrate the existence of clear strain differences in each assay, with 1.2 to 54-fold ranges of sensitivity. All nociceptive assays display moderate-to-high heritability (h2 = 0.30-0.76) and mediation by a limited number of apparent genetic loci. Data comparing inbred strains have considerable utility as a tool for understanding the genetics of nociception, and a particular relevance to transgenic studies.

24 March 2010 in Neuropsychopharmacology
Verified
Journal Article
Closed access
PDF file
MPMichelle C Potter
Michelle C Potter
GEGreg I Elmer
Greg I Elmer
RBRichard Bergeron
Richard Bergeron
EAEdson X Albuquerque
Edson X Albuquerque
PGPaolo Guidetti
Paolo Guidetti
RSRobert Schwarcz
Robert Schwarcz

1 March 1999 in Pain
Verified
Journal Article
Closed access
JMJeffrey S Mogil
Jeffrey S Mogil
SWSonya G Wilson
Sonya G Wilson
KBKarine Bon
Karine Bon
SLSeo Eun Lee
Seo Eun Lee
KCKyungsoon Chung
Kyungsoon Chung
MDMarshall Devor
Marshall Devor
Clinical pain syndromes, and experimental assays of nociception, are differentially affected by manipulations such as drug administration and exposure to environmental stress. This suggests that there are different 'types' of pain. We exploited genetic differences among inbred strains of mice in an attempt to define these primary 'types'; that is, to identify the fundamental parameters of pain processing. Eleven randomly-chosen inbred mouse strains were tested for their basal sensitivity on 12 common measures of nociception. These measures provided for a range of different nociceptive dimensions including noxious stimulus modality, location, duration and etiology, among others. Since individual members of inbred strains are identical at all genetic loci, the observation of correlated strain means in any given pair of nociceptive assays is an index of genetic correlation between these assays, and hence an indication of common physiological mediation. Obtained correlation matrices were subjected to multivariate analyses to identify constellations of nociceptive assays with common genetic mediation. This analysis revealed three major clusters of nociception: (1) baseline thermal nociception, (2) spontaneously-emitted responses to chemical stimuli, and (3) baseline mechanical sensitivity and cutaneous hypersensitivity. Many other nociceptive parameters that might a priori have been considered closely related proved to be genetically divergent.

27 July 2011 in Neuropsychopharmacology
Verified
Journal Article
Closed access
APAna Pocivavsek
Ana Pocivavsek
HWHui-Qiu Wu
Hui-Qiu Wu
MPMichelle C Potter
Michelle C Potter
GEGreg I Elmer
Greg I Elmer
RPRoberto Pellicciari
Roberto Pellicciari
RSRobert Schwarcz
Robert Schwarcz